Navigation Links
Alzheimer's Drug Discovery Foundation Funds American Life Science Pharmaceuticals, Inc to Move Novel Therapeutic Towards Clinic
Date:5/24/2010

NEW YORK, May 24 /PRNewswire-USNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) announced today that it is providing a grant of $248,000 to American Life Science Pharmaceuticals, Inc. (ALSP) to allow for manufacture of its lead drug candidate to be used in preclinical toxicology testing in preparation for entering Phase I clinical trials early in 2011.

ALSP is developing new methods to effectively treat neurodegenerative disease with an initial focus on Alzheimer's disease (AD). ALSP has identified a new class of drugs that prevent memory deficit and pathology in animal models of AD. "Our proprietary lead compound, AB-007, has previously been evaluated for a different indication in human clinical trials and shown to be safe and well tolerated," said company CEO, Michael D. Pierschbacher, PhD. "Our goal is to conduct clinical trials on AB-007 to confirm as soon as possible the observed preclinical efficacy for treatment of AD."

ALSP was recently awarded a National Institute on Aging (NIA) contract to pay for all Investigational New Drug (IND)-enabling toxicology and pharmacology studies. "This ADDF grant combined with the NIA contract makes it possible for us to move this promising Alzheimer's drug through toxicology testing toward the clinic at maximum speed," said Greg Hook, PhD, JD, an ALSP founder. ALSP is currently launching aggressive efforts to raise Series A financing.

ALSP's technology comes out of Vivian Hook, PhD's laboratory at the UCSD Skaggs School of Pharmacy and Pharmaceutical Sciences. Dr. Hook discovered that a novel target enzyme may be responsible for the production of the majority of the beta amyloid peptide in sporadic Alzheimer's disease.  

"The ultimate test for any investigational treatment is in human trials," said the ADDF's executive director, Howard Fillit, MD. "This ADDF grant accelerates AB-007 into clinical testing."

For more information about the ADDF or to speak with Dr. Fillit, please contact Diana Shineman, PhD at 212-901-8007 or dshineman@alzdiscovery.org.  For information about ALSP, Inc. or to speak with Dr. Michael Pierschbacher, call 858-273-3900 or e-mail info@alspinc.com.

About the Alzheimer's Drug Discovery Foundation (www.AlzDiscovery.org)

The ADDF is the only public charity whose sole mission is to accelerate the discovery and development of drugs to prevent, treat and cure Alzheimer's disease, related dementias and cognitive aging. Since 1998, the ADDF has granted more than $40 million to fund over 295 Alzheimer's drug discovery programs in academic centers and biotechnology companies in 15 countries. 

About American Life Science Pharmaceuticals, Inc. (www.alspinc.com)

ALSP is a privately held company located in San Diego, CA. The company and its world class team is passionate about finding a drug that prevents the devastation that is Alzheimer's disease.  We believe that our lead candidate, AB-007, represents a first-in-class drug that has an excellent chance to meet that challenge. ALSP is poised to enter the crucible of the clinic to put its approach to the test.


'/>"/>
SOURCE Alzheimer's Drug Discovery Foundation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
2. New Company Starts, Bridging the Development Gap in the Discovery of Cancer Drugs
3. Trana Discovery and Southern Research Institute Announce the First RNA-RNA High Throughput Drug Screening Assay Platform for HIV Antivirals
4. ActiveSight and CHDI Leverage Fragment-Based Lead Discovery for Huntington Disease Therapies
5. ARCA Discovery Announces Data Demonstrating Potential for Bucindolol as Targeted Therapy in Heart Failure, Atrial Fibrillation, and Ventricular Arrhythmia
6. Five Clinical Studies to Receive $2.5 Million Under Foundations 2007 Clinical Discovery Program
7. Ambrx Enters FGF-21 Type 2 Diabetes Drug Discovery Collaboration with Merck and Co. Inc.
8. FASgen Announces New Discovery for Treatment of Stroke
9. Nobel Prize-Winning Discovery
10. Orion Genomics Announces the Discovery of Novel Breast Cancer Biomarkers
11. FASgen Announces a New Discovery in Obesity Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2017)... It should come as no surprise to anyone that ... of a crippling opioid epidemic. According to the Center ... deaths from opiate-based medications has quadrupled, Says, Dr. David ... 2001 to 2015". During this time, the prescription rate for ... a compelling link between prescription and eventual addiction. The problem ...
(Date:7/12/2017)... ANGELES , July 12, 2017 CarpalAID is a ... drugs, braces or surgery. Carpal tunnel syndrome affects more ... syndrome at twice the rate of men. The common methods of ... or mobilization with uncomfortable hand braces or gloves. ... CarpalAID is a clear ...
(Date:7/11/2017)... July 11, 2017  The global market for liquid ... approximately $394.1 million in 2016.  Although in early stages, ... growth, in particular as a result of the gradual ... the recent introduction of a significant number of new ... testing of tumor biomarkers to guide treatment decisions. ...
Breaking Medicine Technology:
(Date:7/28/2017)... ... July 28, 2017 , ... The ... of America (MOAA), has announced the grant recipients of its inaugural community outreach ... grants:, , Falcon’s Landing Chapter, Sterling, Va.: $5,000. Community ...
(Date:7/28/2017)... ... July 28, 2017 , ... Art has the power to ... program encourages patients and residents to flex their creative arms. This year’s Reflect N ... have voted on their favorite piece. , The 2017 Reflect N Us winner ...
(Date:7/28/2017)... ... July 28, 2017 , ... ... of its budget on nutrition assistance programs. , Right now the most public ... . However, changes to other programs are under consideration, including WIC (Women, Infants, ...
(Date:7/28/2017)... ... July 28, 2017 , ... Join Becker's Healthcare as they host their ... in Chicago IL. Great sessions on Epic, Cyber Security, Telehealth, Mobile Health, Revenue Cycle ... talks by:, George W. Bush, 43rd President of the ...
(Date:7/28/2017)... ... July 28, 2017 , ... ... Shamanic Healing and Spiritual Awakening, is proud to announce the return of ... , Those interested in learning more about the mystical world of shamanism, nature ...
Breaking Medicine News(10 mins):